Brind.

Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.

3 reports, 2 independent Updated Aug 1

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.

Who's involved

What this event is mainly about

Merck KGaA Eli Lilly and Company Biogen Eisai

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
Eli Lilly and Company
American pharmaceutical company
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
- The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
Biogen
American multinational biotechnology company

Nothing else this week.
Eisai
Japanese pharmaceutical company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 1Pharma VoiceMerck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily Pharm
Jul 31Investing.comBiogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted b
Jul 3Unknown outlet